![Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial - The Lancet Digital Health Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial - The Lancet Digital Health](https://www.thelancet.com/cms/attachment/31ab2e41-de82-46ba-bf47-7bbc7aa60083/gr1.gif)
Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial - The Lancet Digital Health
![Figure 1 from Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions | Semantic Scholar Figure 1 from Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a29b57f940517cbc5d3062983b1d05bb0089cd21/2-Figure1-1.png)
Figure 1 from Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions | Semantic Scholar
![Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study](https://bmjopen.bmj.com/content/bmjopen/11/2/e042790/F1.large.jpg)
Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study
![Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study - The Lancet Healthy Longevity Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study - The Lancet Healthy Longevity](https://www.thelancet.com/cms/attachment/26c5b81b-110c-4855-8c0d-6b6bce766829/gr1_lrg.jpg)